RNA-based approaches have emerged as promising strategies for cancer treatment, providing innovative solutions to target specific genetic abnormalities associated with tumorigenesis. Among these approaches, the development and assessment of Antisense Oligonucleotides (ASOs) for targeted exon skipping have gained significant attention. In this article, we delve into the intricacies of RNA-based cancer treatment, focusing on the in silico methods employed in the design and evaluation of ASOs for exon skipping. We explore the molecular underpinnings of cancer, the role of RNA in disease progression, and the potential of ASOs to modulate gene expression with precision. Through an in-depth analysis of computational tools and techniques, we evaluate the effectiveness of ASOs in silico, paving the way for enhanced therapeutic outcomes in the realm of cancer treatment.
HTML PDFShare this article
Molecular and Genetic Medicine received 3919 citations as per Google Scholar report
